In the past several years, major heart failure guidelines have undergone a significant shift: SGLT2 inhibitors are now considered foundational therapy for patients with reduced or preserved ejection ...

A new review finds that combining SGLT2 inhibitors with GLP-1 receptor agonists in heart failure is mechanistically plausible ...

Research led by internist-nephrologist Dr. Michele Eisenga shows that SGLT2 inhibitors, a class of drugs widely used to treat ...

A meta-analysis of three randomized trials found modest reductions in functional mitral regurgitation with SGLT2 inhibitors, ...

SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease. However, there have been questions as to whether it is safe to use these drugs in patients ...

CHICAGO — For older patients at high risk for a heart failure event who are scheduled for transcatheter aortic valve implantation (TAVI), dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) ...

A drug that can both decrease the risk for diabetes along with the risk for having a heart attack or stroke could be a ...

Although the beneficial effects of sodium–glucose cotransporter 2 (SGLT2) inhibition in heart failure (HF) have been well established, it is unknown whether SGLT2 inhibition confers benefit in ...

In recent years,SGLT2 inhibitors, including dapagliflozin and empagliflozin.These have established a firm position as ...

Please provide your email address to receive an email when new articles are posted on . A digital strategy increased uptake of SGLT2 inhibitors compared with usual care in patients with heart failure.

"Modest rise" in hemoglobin concentration could still help in chronic anemia management ...

SGLT2 inhibitors now have strong evidence and approvals for heart failure (HFrEF/HFpEF) and chronic kidney disease, which enlarged the treatable patient pool well beyond people with type 2 diabetes.